COVID-19 and the nicotinic cholinergic system #MMPMID32444400
Farsalinos K; Angelopoulou A; Alexandris N; Poulas K
Eur Respir J 2020[Jul]; 56 (1): ä PMID32444400show ga
The prevalence of smoking among hospitalised COVID-19 patients is low. COVID-19 manifestations could be linked to impairment of the cholinergic anti-inflammatory pathway. Nicotinic cholinergic agonists should be examined as potential therapeutic options. https://bit.ly/2zfUZ1S